Literature DB >> 35467005

MiR-486-5p specifically suppresses SAPCD2 expression, which attenuates the aggressive phenotypes of lung adenocarcinoma cells.

Desheng Wei1.   

Abstract

BACKGROUND: MiR-486-5p expression is restrained in lung adenocarcinoma (LUAD). However, much less has been understood on its role in LUAD. We aimed to explore the biofunctions of miR-486-5p in LUAD.
METHODS: A differential expression analysis based on The Cancer Genome Atlas-LUAD dataset was done to screen the differently expressed miRNAs and mRNAs. MiR-486-5p and SAPCD2 mRNA expression was analyzed by qRT-PCR, and protein level of SAPCD2 was assayed by western blot. Upregulation and downregulation of miR-486-5p or SAPCD2 were achieved by cell transfection. For cell function assays, the proliferation of cancer cells was examined by MTT assay. Cell apoptosis was assessed by flow cytometry and microscopy. Transwell assay was applied to evaluate cell migration and invasion. A dual-luciferase detection was employed to determine the miRNA-mRNA targeting relationship.
RESULTS: MiR-486-5p expression was notably reduced in LUAD tissue and cell lines. Upregulating miR-486-5p restrained the anti-apoptotic and proliferative abilities, as well as cell migratory and invasive phenotypes in LUAD cells. SAPCD2 was determined as one target of miR-486-5p. Also, SAPCD2 forced expression was able to attenuate the inhibitory impacts of miR-486-5p on the malignant phenotypes of LUAD cells.
CONCLUSION: MiR-486-5p suppressed cell malignant progression in LUAD by targeting SAPCD2, suggesting that the two may be targets for LUAD treatment. ©The Author(s) 2022. Open Access. This article is licensed under a Creative Commons CC-BY International License.

Entities:  

Year:  2022        PMID: 35467005     DOI: 10.14670/HH-18-463

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  31 in total

1.  Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-β-activated kinase 1.

Authors:  Yanfa He; Jianzhen Liu; Yongjun Wang; Xiaoli Zhu; Zhengchao Fan; Chongbin Li; Hang Yin; Ying Liu
Journal:  J Cell Biochem       Date:  2018-12-09       Impact factor: 4.429

Review 2.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay.

Authors:  Eric Huntzinger; Elisa Izaurralde
Journal:  Nat Rev Genet       Date:  2011-02       Impact factor: 53.242

Review 3.  MicroRNAs: Biomarkers, Diagnostics, and Therapeutics.

Authors:  Weili Huang
Journal:  Methods Mol Biol       Date:  2017

4.  Targeting of SGK1 by miR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion.

Authors:  Evan J Greenawalt; Mick D Edmonds; Neha Jain; Clare M Adams; Ramkrishna Mitra; Christine M Eischen
Journal:  Mol Cancer Res       Date:  2018-09-26       Impact factor: 5.852

5.  SAPCD2 Controls Spindle Orientation and Asymmetric Divisions by Negatively Regulating the Gαi-LGN-NuMA Ternary Complex.

Authors:  Catherine W N Chiu; Carine Monat; Mélanie Robitaille; Marine Lacomme; Avais M Daulat; Graham Macleod; Helen McNeill; Michel Cayouette; Stéphane Angers
Journal:  Dev Cell       Date:  2016-01-11       Impact factor: 12.270

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Long noncoding RNA PXN-AS1-L promotes the malignancy of nasopharyngeal carcinoma cells via upregulation of SAPCD2.

Authors:  Xiaodong Jia; Po Niu; Cuncun Xie; Hongjian Liu
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

8.  MiR-486-5p Suppresses Proliferation and Migration of Hepatocellular Carcinoma Cells through Downregulation of the E3 Ubiquitin Ligase CBL.

Authors:  Jia He; Bin Xiao; Xiaoyan Li; Yongyin He; Linhai Li; Zhaohui Sun
Journal:  Biomed Res Int       Date:  2019-12-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.